Digoxin Tied to Higher Mortality in Patients With Atrial Fibrillation

Share this content:
Digoxin Tied to Higher Mortality in Patients With Atrial Fibrillation
Digoxin Tied to Higher Mortality in Patients With Atrial Fibrillation

WEDNESDAY, March 14, 2018 (HealthDay News) -- Digoxin is independently associated with higher mortality in patients with atrial fibrillation (AF) regardless of whether they have heart failure, according to a study published in the March 13 issue of the Journal of the American College of Cardiology.

Renato D. Lopes, M.D., Ph.D., from the Duke University School of Medicine in Durham, N.C., and colleagues examined whether digoxin use was independently associated with increased mortality in 17,897 patients with AF and whether the association was modified by heart failure and/or serum digoxin concentration.

The researchers found that at baseline, just under one-third of patients (5,824) were receiving digoxin. There was no increased risk of death associated with baseline digoxin use (adjusted hazard ratio [HR], 1.09; 95 percent confidence interval, 0.96 to 1.23; P = 0.19). However, compared with patients not on digoxin, patients with a serum digoxin concentration ≥1.2 ng/mL had a 56 percent increased hazard of mortality (adjusted HR, 1.56; 95 percent confidence interval, 1.2 to 2.04). For each 0.5-ng/mL increase (P = 0.001), there was a 19 percent higher adjusted hazard for death, and these results were similar in patients with and without heart failure. Compared with propensity score-matched controls, new digoxin users had a significantly increased risk of death (adjusted HR, 1.78; 95 percent confidence interval, 1.37 to 2.31) and sudden death (adjusted HR, 2.14; 95 percent confidence interval, 1.11 to 4.12.)

"Initiating digoxin was independently associated with higher mortality in patients with AF, regardless of heart failure," the authors write.

Several authors disclosed financial ties to medical device and pharmaceutical companies, including Bristol-Myers Squibb and Pfizer, which funded the study.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

USPSTF Urges Abuse Screening for Reproductive-Aged Women

USPSTF Urges Abuse Screening for Reproductive-Aged Women

Evidence lacking for assessing balance of benefits, harms of screening for abuse of seniors, vulnerable

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Increased likelihood of clinical and microbiological resolution for uncomplicated UTI in women

Exercise Intervention Doesn't Improve Walking Ability in PAD

Exercise Intervention Doesn't Improve Walking Ability in PAD

Smaller mean change from baseline to follow-up in 6-minute walking distance with exercise intervention

is free, fast, and customized just for you!

Already a member?

Sign In Now »